文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

心脏生物标志物与阿夫凯泰在梗阻性肥厚型心肌病中的效应:SEQUOIA-HCM试验

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
PubMed 文献 · Eur Heart J · 2024-01-01

SEQUOIA-HCM预设分析探讨梗阻性肥厚型心肌病中NT-proBNP与hs-cTnI的关联及阿夫凯泰的影响。基线NT-proBNP与LVOT-G及舒张功能相关,hs-cTnI与左室厚度相关。阿夫凯泰治疗8周内NT-proBNP降低79%、hs-cTnI降低41%,洗脱后回升,24周降幅与LVOT-G下降、健康状况改善及峰值氧摄取量增加强相关。

要点

  • 基线NT-proBNP关联LVOT-G与舒张功能,hs-cTnI关联左室厚度
  • 阿夫凯泰8周内NT-proBNP降79%、hs-cTnI降41%,洗脱后回到基线
  • 24周生物标志物降幅与LVOT-G下降、健康状况及峰值氧摄取量改善强相关

核心结论

  • NT-proBNP和hs-cTnI浓度与梗阻性肥厚型心肌病关键变量相关,系列检测可反映阿夫凯泰治疗的临床反应。

研究设计与样本

  • SEQUOIA-HCM(NCT05186818)预设分析,基线与研究期间系列测量心脏生物标志物,用回归分析确定预测因素并评估早期变化与后期终点的关系。

主要发现

  • 基线NT-proBNP与LVOT-G及舒张功能指标相关,hs-cTnI与左室厚度相关。
  • 阿夫凯泰治疗8周内NT-proBNP降低79%(95%CI 76%-83%,P<.001),hs-cTnI降低41%(95%CI 32%-49%,P<.001),洗脱后均回到基线。
  • 24周NT-proBNP和hs-cTnI降幅与LVOT-G降低、健康状况改善及峰值氧摄取量增加强相关。
  • NT-proBNP降幅与多数运动能力改善强相关,第2周NT-proBNP变化与24周关键终点变化相关。

临床怎么用

  • 系列检测NT-proBNP和hs-cTnI可能有助于评估梗阻性肥厚型心肌病患者对阿夫凯泰的治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), and to evaluate the effect of treatment with aficamten on biomarker concentrations. METHODS: Cardiac biomarkers were measured at baseline and serially throughout the study. Regression analyses determined predictors of baseline NT-proBNP and hs-cTnI concentrations, and evaluated whether early changes in these biomarkers relate to later changes in left ventricular outflow tract gradient (LVOT-G), other echocardiographic measures, health status, and functional capacity. RESULTS: Baseline concentration of NT-proBNP was associated with LVOT-G and measures of diastolic function, while hs-cTnI was associated with left ventricular thickness. Within 8 weeks of treatment with aficamten, NT-proBNP was reduced by 79% (95% confidence interval 76%-83%, P < .001) and hs-cTnI by 41% (95% confidence interval 32%-49%, P < .001); both biomarkers reverted to baseline after washout. Reductions in NT-proBNP and hs-cTnI by 24 weeks were strongly associated with a lowering of LVOT-G, improvement in health status, and increased peak oxygen uptake. N-Terminal pro-B-type natriuretic peptide reduction strongly correlated with the majority of improvements in exercise capacity. Furthermore, the change in NT-proBNP by Week 2 was associated with the 24-week change in key endpoints. CONCLUSIONS: N-Terminal pro-B-type natriuretic peptide and hs-cTnI concentrations are associated with key variables in obstructive hypertrophic cardiomyopathy. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Coats CJ, Masri A, Barriales-Villa R, et al. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024. PMID: 39217447. doi:10.1093/eurheartj/ehae590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。